On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Abstract:
Accession Therapeutics has developed a unique viral expression system (Trocept), the first-of-its-kind engineered NOT to infect healthy tissue, that can be administered intravenously and only infect cells expressing avb6 integrin. Accession is focussing this viral platform on cancer treatment, but recent evidence has implicated avb6 integrin in endometriosis lesions. The TROCEPT platform can be loaded with transgenes (bits of DNA) encoding protein based therapeutic drugs (like antibodies) for expression only in diseased tissues (i.e., TROCEPT can deliver the transgene ‘drug’ into a target cell, turning it into a drug factory, which releases the payload into the local diseased tissue).
Biography:
Dave is a recognised expert in immune-oncology with over 15 years’ experience, including research leading to the discovery and validation of novel drug candidates plus development of collaborations with academia and industry. In his academic career Dave has published over 100 articles, and worked as a principal investigator and Wellcome Trust Fellow at Cardiff University, where he also carried out postdoctoral work after he received his D.Phil in Molecular Immunology from the University of Oxford.
